2021 Q1 Form 10-Q Financial Statement
#000156459021024931 Filed on May 06, 2021
Income Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $8.130M | $3.990M |
| YoY Change | 103.76% | 175.17% |
| % of Gross Profit | ||
| Research & Development | $23.57M | $14.58M |
| YoY Change | 61.64% | 146.67% |
| % of Gross Profit | ||
| Depreciation & Amortization | $673.0K | $200.0K |
| YoY Change | 236.5% | 75.44% |
| % of Gross Profit | ||
| Operating Expenses | $31.71M | $18.57M |
| YoY Change | 70.71% | 152.45% |
| Operating Profit | -$31.71M | -$18.57M |
| YoY Change | 70.71% | 152.45% |
| Interest Expense | ||
| YoY Change | ||
| % of Operating Profit | ||
| Other Income/Expense, Net | $62.00K | $949.0K |
| YoY Change | -93.47% | -939.82% |
| Pretax Income | -$31.64M | -$17.62M |
| YoY Change | 79.57% | 135.88% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$31.64M | -$17.62M |
| YoY Change | 79.55% | 135.93% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$949.3K | -$577.9K |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $331.7M | $206.8M |
| YoY Change | 60.42% | |
| Cash & Equivalents | $252.4M | $48.06M |
| Short-Term Investments | $79.30M | $158.7M |
| Other Short-Term Assets | $9.500M | $5.700M |
| YoY Change | 66.67% | |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $341.2M | $212.5M |
| YoY Change | 60.55% | |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $25.65M | $4.683M |
| YoY Change | 447.79% | |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $12.20M | |
| YoY Change | ||
| Other Assets | $886.0K | $258.0K |
| YoY Change | 243.41% | |
| Total Long-Term Assets | $39.32M | $30.64M |
| YoY Change | 28.32% | |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $341.2M | $212.5M |
| Total Long-Term Assets | $39.32M | $30.64M |
| Total Assets | $380.5M | $243.2M |
| YoY Change | 56.49% | |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $5.700M | $1.984M |
| YoY Change | 187.3% | |
| Accrued Expenses | $5.826M | $3.031M |
| YoY Change | 92.21% | |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $14.82M | $7.544M |
| YoY Change | 96.42% | |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $10.00M | $11.60M |
| YoY Change | -13.79% | |
| Total Long-Term Liabilities | $10.00M | $11.60M |
| YoY Change | -13.79% | |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $14.82M | $7.544M |
| Total Long-Term Liabilities | $10.00M | $11.60M |
| Total Liabilities | $24.86M | $19.14M |
| YoY Change | 29.91% | |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$220.2M | -$124.8M |
| YoY Change | 76.4% | |
| Common Stock | $575.7M | $348.6M |
| YoY Change | 65.17% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $355.6M | $224.0M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $380.5M | $243.2M |
| YoY Change | 56.48% |
Cashflow Statement
| Concept | 2021 Q1 | 2020 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$31.64M | -$17.62M |
| YoY Change | 79.55% | 135.93% |
| Depreciation, Depletion And Amortization | $673.0K | $200.0K |
| YoY Change | 236.5% | 75.44% |
| Cash From Operating Activities | -$28.26M | -$16.39M |
| YoY Change | 72.47% | 96.37% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $6.073M | $1.705M |
| YoY Change | 256.19% | 138.46% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $45.68M | $88.00M |
| YoY Change | -48.09% | |
| Cash From Investing Activities | $39.61M | $28.53M |
| YoY Change | 38.84% | -4090.07% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | -53.00K | 22.00K |
| YoY Change | -340.91% | -99.78% |
| NET CHANGE | ||
| Cash From Operating Activities | -28.26M | -16.39M |
| Cash From Investing Activities | 39.61M | 28.53M |
| Cash From Financing Activities | -53.00K | 22.00K |
| Net Change In Cash | 11.30M | 12.16M |
| YoY Change | -7.14% | 1150.15% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$28.26M | -$16.39M |
| Capital Expenditures | $6.073M | $1.705M |
| Free Cash Flow | -$34.34M | -$18.09M |
| YoY Change | 89.78% | 99.69% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2021Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2021Q1 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2020 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y9M18D | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P8Y | |
| CY2021Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y9M18D | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P3Y8M12D | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P4Y1M6D | |
| CY2021Q1 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
14818000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10046000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
25542931 | |
| CY2021Q1 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
12758000 | |
| CY2021Q1 | us-gaap |
Common Stock Value
CommonStockValue
|
255000 | |
| CY2021Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
886000 | |
| CY2020Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
255000 | |
| CY2021Q1 | us-gaap |
Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
|
575481000 | |
| CY2021Q1 | us-gaap |
Liabilities
Liabilities
|
24864000 | |
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000000000 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
25581212 | |
| CY2021Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
25581212 | |
| CY2021Q1 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
14000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-220204000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
355610000 | |
| CY2020Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
4925000 | |
| CY2021Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
67000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
25542931 | |
| CY2020Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
17240000 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
25653000 | |
| CY2021Q1 | us-gaap |
Assets Current
AssetsCurrent
|
341177000 | |
| CY2020Q4 | us-gaap |
Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
|
11586000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2667000 | |
| CY2020Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
548000 | |
| CY2020Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
1000000000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
9577000 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2020Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
26000 | |
| CY2020Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
14583000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31644000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17624000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-12000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
162000 | |
| CY2021Q1 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
380474000 | |
| CY2021Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
23572000 | |
| CY2021Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
8134000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
3990000 | |
| CY2021Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
31706000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
18573000 | |
| CY2021Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-31706000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-18573000 | |
| CY2021Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
62000 | |
| CY2020Q1 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
949000 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31644000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17624000 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.95 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.58 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33328994 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
30491463 | |
| CY2021Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-31656000 | |
| CY2020Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-17462000 | |
| CY2020Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
381815000 | |
| CY2021Q1 | igms |
Stock Issued During Period Value Exercise Of Stock Options Net Of Shares Withheld For Taxes And Exercise Costs
StockIssuedDuringPeriodValueExerciseOfStockOptionsNetOfSharesWithheldForTaxesAndExerciseCosts
|
-53000 | |
| CY2021Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-12000 | |
| CY2021Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
5504000 | |
| CY2021Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
355610000 | |
| CY2019Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
240231000 | |
| CY2021Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-31644000 | |
| CY2020Q1 | us-gaap |
Profit Loss
ProfitLoss
|
-17624000 | |
| CY2021Q1 | us-gaap |
Depreciation
Depreciation
|
673000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
222000 | |
| CY2021Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
5504000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1323000 | |
| CY2021Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
-195000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
306000 | |
| CY2021Q1 | igms |
Non Cash Lease Expense
NonCashLeaseExpense
|
672000 | |
| CY2020Q1 | igms |
Non Cash Lease Expense
NonCashLeaseExpense
|
629000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
2500000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-735000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
|
338000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
|
-35000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
1045000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
6073000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
1705000 | |
| CY2021Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
12989000 | |
| CY2021Q1 | us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
418000 | |
| CY2021Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
365000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-53000 | |
| CY2021Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
11296000 | |
| CY2020Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
241080000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
41131000 | |
| CY2021Q1 | us-gaap |
Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
|
58673000 | |
| CY2021Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-1158000 | |
| CY2021Q1 | igms |
Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
|
-711000 | |
| CY2021Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-28262000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-16387000 | |
| CY2021Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
856000 | |
| CY2020Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
280000 | |
| CY2021Q1 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-220200000 | |
| CY2021Q1 | us-gaap |
Investments And Cash
InvestmentsAndCash
|
331700000 | |
| CY2021Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates, including, but not limited to, those related to investments, manufacturing accruals, accrued research and development expenses, fair value of common stock, stock-based compensation, <span style="color:#000000;">operating lease right-of-use (ROU) assets and liabilities, </span>income tax uncertainties and the valuation of deferred tax assets. The Company bases its estimates on its historical experience and also on assumptions that it believes are reasonable; however, actual results could significantly differ from those estimates.</p> | |
| CY2021Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:6pt;"> </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to a concentration of credit risk consist primarily of cash and investments. The Company invests in money market funds, U.S. Treasury securities, corporate bonds, commercial paper, and U.S. government agency securities. The Company maintains bank deposits in federally insured financial institutions and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and issuers of investments to the extent recorded on the balance sheets. The Company’s investment policy limits investments to money market funds, certain types of debt securities issued by the U.S. Government and its agencies, corporate debt, commercial paper, and places restrictions on the credit ratings, maturities and concentration by type and issuer. The Company has not experienced any losses on its deposits of cash and investments.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company’s future operating results and cause actual results to vary materially from expectations include, but are not limited to, the Company’s early stages of clinical drug development; uncertainties related to the use of engineered IgM antibodies, which is a novel and unproven therapeutic approach; the Company’s ability to advance product candidates into, and successfully complete, clinical trials on the timelines it projects; the Company’s ability to adequately demonstrate sufficient safety and efficacy of its product candidates; the Company’s ability to enroll patients in its ongoing and future clinical trials; the Company’s ability to successfully manufacture and supply its product candidates for clinical trials; the Company’s ability to obtain additional capital to finance its operations; uncertainties related to the projections of the size of patient populations suffering from the diseases the Company is targeting; the Company’s ability to obtain, maintain, and protect its intellectual property rights; developments relating to the Company’s competitors and its industry, including competing product candidates and therapies; general economic and market conditions; and other risks and uncertainties, including those more fully described in the “Risk Factors” section of this Quarterly Report on Form 10-Q.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s product candidates will require approvals from the U.S. Food and Drug Administration (FDA) and comparable foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed or the Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company.</p> | |
| CY2021Q1 | igms |
Number Of Financial Instruments Classified As Level Three
NumberOfFinancialInstrumentsClassifiedAsLevelThree
|
0 | |
| CY2020Q4 | igms |
Number Of Financial Instruments Classified As Level Three
NumberOfFinancialInstrumentsClassifiedAsLevelThree
|
0 | |
| CY2020Q4 | igms |
Cash And Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
|
364723000 | |
| CY2021Q1 | igms |
Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
|
330319000 | |
| CY2021Q1 | igms |
Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
15000 | |
| CY2021Q1 | igms |
Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1000 | |
| CY2021Q1 | igms |
Cash And Cash Equivalents And Available For Sale Securities Debt Securities Fair Value
CashAndCashEquivalentsAndAvailableForSaleSecuritiesDebtSecuritiesFairValue
|
330333000 | |
| CY2020Q4 | igms |
Cash And Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
|
364697000 | |
| CY2020Q4 | igms |
Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
27000 | |
| CY2020Q4 | igms |
Cash And Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashAndCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1000 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
28615000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
25515000 | |
| CY2021Q1 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2962000 | |
| CY2020Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2289000 | |
| CY2021Q1 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
25653000 | |
| CY2020Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
23226000 | |
| CY2021Q1 | us-gaap |
Depreciation
Depreciation
|
700000 | |
| CY2020Q1 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2021Q1 | igms |
Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
|
2754000 | |
| CY2020Q4 | igms |
Accrued Research And Development Materials And Services Current
AccruedResearchAndDevelopmentMaterialsAndServicesCurrent
|
1509000 | |
| CY2021Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
98000 | |
| CY2020Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
163000 | |
| CY2021Q1 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
2907000 | |
| CY2020Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
52000 | |
| CY2021Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
5826000 | |
| CY2020Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
6649000 | |
| CY2021Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
200000000 | |
| CY2020Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
200000000 | |
| CY2021Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2020Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.01 | |
| CY2020Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.01 | |
| CY2021Q1 | us-gaap |
Common Stock Voting Rights
CommonStockVotingRights
|
Each share of common stock (excluding non-voting common stock) is entitled to one vote | |
| CY2021Q1 | igms |
Number Of Voting Rights For Each Common Stock Held
NumberOfVotingRightsForEachCommonStockHeld
|
1 | |
| CY2021Q1 | us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | |
| CY2020 | us-gaap |
Dividends Common Stock
DividendsCommonStock
|
0 | |
| CY2021Q1 | igms |
Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
|
3603469 | |
| CY2020Q4 | igms |
Stock Options Issued And Outstanding
StockOptionsIssuedAndOutstanding
|
2926560 | |
| CY2021Q1 | igms |
Restricted Stock Units
RestrictedStockUnits
|
417 | |
| CY2020Q4 | igms |
Restricted Stock Units
RestrictedStockUnits
|
667 | |
| CY2021Q1 | igms |
Stock Options And Restricted Stock Units Future Issuance
StockOptionsAndRestrictedStockUnitsFutureIssuance
|
3615393 | |
| CY2020Q4 | igms |
Stock Options And Restricted Stock Units Future Issuance
StockOptionsAndRestrictedStockUnitsFutureIssuance
|
3054127 | |
| CY2021Q1 | igms |
Employee Stock Purchase Plan Number Of Shares Available For Grant
EmployeeStockPurchasePlanNumberOfSharesAvailableForGrant
|
873829 | |
| CY2020Q4 | igms |
Employee Stock Purchase Plan Number Of Shares Available For Grant
EmployeeStockPurchasePlanNumberOfSharesAvailableForGrant
|
554088 | |
| CY2021Q1 | igms |
Pre Funded Warrants
PreFundedWarrants
|
1334332 | |
| CY2020Q4 | igms |
Pre Funded Warrants
PreFundedWarrants
|
1334332 | |
| CY2021Q1 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
9427440 | |
| CY2020Q4 | us-gaap |
Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
|
7869774 | |
| CY2020Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
0.01 | |
| CY2020Q4 | igms |
Maximum Allowed Holding Percentage Of Shares After Exercise Of Warrants
MaximumAllowedHoldingPercentageOfSharesAfterExerciseOfWarrants
|
0.0999 | |
| CY2020Q4 | igms |
Maximum Allowed Combined Voting Percentage Of Shares After Exercise Of Warrants
MaximumAllowedCombinedVotingPercentageOfSharesAfterExerciseOfWarrants
|
0.0999 | |
| CY2020Q4 | igms |
Maximum Allowed Percentage Of Pre Funded Warrants To Exercise
MaximumAllowedPercentageOfPreFundedWarrantsToExercise
|
0.1999 | |
| CY2020Q4 | igms |
Minimum Notice Term To Increase Or Decrease Holding Percentage Of Pre Funded Warrants
MinimumNoticeTermToIncreaseOrDecreaseHoldingPercentageOfPreFundedWarrants
|
P61D | |
| CY2021Q1 | igms |
Number Of Warrants Exercised
NumberOfWarrantsExercised
|
0 | |
| CY2021Q1 | igms |
Accrued Share Based Compensation Expense
AccruedShareBasedCompensationExpense
|
0 | |
| CY2020Q1 | igms |
Accrued Share Based Compensation Expense
AccruedShareBasedCompensationExpense
|
100000 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
2926560 | |
| CY2020Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
15.54 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
724052 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
89.76 | |
| CY2021Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
42002 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
9.10 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
5141 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
57.15 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
3603469 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
30.47 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
1610513 | |
| CY2021Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
9.10 | |
| CY2021Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-31644000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17624000 | |
| CY2021Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
33328994 | |
| CY2020Q1 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
30491463 | |
| CY2021Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.95 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.58 | |
| CY2021Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3611734 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3017673 | |
| CY2021Q1 | igms |
Number Of Lease Agreements
NumberOfLeaseAgreements
|
3 | |
| CY2021Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
761000 | |
| CY2020Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
740000 | |
| CY2021Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
786000 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
767000 | |
| CY2021Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
71000 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
46000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
3331000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
2667000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
10046000 | |
| CY2020Q4 | us-gaap |
Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
|
9577000 | |
| CY2021Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.036 | |
| CY2020Q4 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.038 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
2788000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
3949000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3860000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
3008000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
733000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
14338000 | |
| CY2021Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
961000 | |
| CY2021Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
13377000 |
